Corvus Pharmaceuticals Stock Total Debt
| CRVS Stock | USD 8.93 0.02 0.22% |
Corvus Pharmaceuticals fundamentals help investors to digest information that contributes to Corvus Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Corvus Stock. The fundamental analysis module provides a way to measure Corvus Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Corvus Pharmaceuticals stock.
Total Debt To Capitalization is likely to drop to 0.03 in 2024. Corvus | Total Debt |
Corvus Pharmaceuticals Company Total Debt Analysis
Corvus Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Corvus Pharmaceuticals Total Debt | 1.37 M |
Most of Corvus Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Corvus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Corvus Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Corvus Pharmaceuticals is extremely important. It helps to project a fair market value of Corvus Stock properly, considering its historical fundamentals such as Total Debt. Since Corvus Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Corvus Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Corvus Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Corvus Total Debt Historical Pattern
Today, most investors in Corvus Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Corvus Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Corvus Pharmaceuticals total debt as a starting point in their analysis.
Corvus Pharmaceuticals Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Corvus Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Corvus Pharmaceuticals has a Total Debt of 1.37 M. This is 99.95% lower than that of the Biotechnology sector and 99.58% lower than that of the Health Care industry. The total debt for all United States stocks is 99.97% higher than that of the company.
Corvus Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Corvus Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Corvus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Corvus Pharmaceuticals by comparing valuation metrics of similar companies.Corvus Pharmaceuticals is currently under evaluation in total debt category among its peers.
Corvus Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Corvus Pharmaceuticals from analyzing Corvus Pharmaceuticals' financial statements. These drivers represent accounts that assess Corvus Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Corvus Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 159.7M | 104.9M | 100.9M | 39.6M | 84.5M | 140.7M | |
| Enterprise Value | 157.7M | 90.8M | 41.1M | 29.0M | 73.3M | 80.6M |
Corvus Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Corvus Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Corvus Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Corvus Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Corvus Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Corvus Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Corvus Pharmaceuticals' value.| Shares | Schonfeld Strategic Advisors Llc | 2024-09-30 | 331.4 K | Millennium Management Llc | 2024-06-30 | 204.6 K | Bridgeway Capital Management, Llc | 2024-09-30 | 127.3 K | Citigroup Inc | 2024-09-30 | 122.9 K | State Street Corp | 2024-06-30 | 120.3 K | Towerview Llc | 2024-09-30 | 117.5 K | Two Sigma Advisers, Llc | 2024-06-30 | 113.4 K | Northern Trust Corp | 12241224-09-30 | 105.5 K | Citadel Advisors Llc | 2024-09-30 | 97.1 K | Orbimed Advisors, Llc | 2024-06-30 | 6.9 M | Point72 Asset Management, L.p. | 2024-09-30 | 5.6 M |
Corvus Fundamentals
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 533.81 M | ||||
| Shares Outstanding | 64.26 M | ||||
| Shares Owned By Insiders | 4.02 % | ||||
| Shares Owned By Institutions | 44.47 % | ||||
| Number Of Shares Shorted | 2.93 M | ||||
| Price To Earning | (5.64) X | ||||
| Price To Book | 46.35 X | ||||
| EBITDA | (26.88 M) | ||||
| Net Income | (27.03 M) | ||||
| Cash And Equivalents | 56.72 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 1.37 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 5.80 X | ||||
| Book Value Per Share | 0.79 X | ||||
| Cash Flow From Operations | (23.93 M) | ||||
| Short Ratio | 3.82 X | ||||
| Earnings Per Share | (0.99) X | ||||
| Target Price | 15.75 | ||||
| Number Of Employees | 28 | ||||
| Beta | 1.04 | ||||
| Market Capitalization | 575.1 M | ||||
| Total Asset | 45.55 M | ||||
| Retained Earnings | (334.72 M) | ||||
| Working Capital | 21.09 M | ||||
| Current Asset | 78.53 M | ||||
| Current Liabilities | 6.42 M | ||||
| Net Asset | 45.55 M |
About Corvus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Corvus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Corvus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Corvus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.